Navigation Links
Anesiva and Sigma-Tau Announce Exclusive Marketing and Distribution Agreement for Zingo(TM) in Six European Countries
Date:2/11/2008

SOUTH SAN FRANCISCO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) and Sigma-Tau SpA have announced an agreement granting an exclusive license to Sigma-Tau for the marketing and distribution of Anesiva's Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system in six European countries: Italy, France, Germany, Netherlands, Belgium and Luxembourg. Under the terms of the agreement, Sigma-Tau will oversee all necessary regulatory filings, and will be responsible for all marketing and sales of Zingo in their territory.

"In Sigma-Tau, we have selected an experienced partner that can quickly and effectively maximize the Zingo opportunity in Europe and we look forward to an excellent collaborative relationship. Sigma-Tau has a proven commercial infrastructure, including a hospital sales force, and a strong network in Europe," said John P. McLaughlin, chief executive officer of Anesiva. "This licensing agreement covers the majority of Europe and we are currently in advanced discussions with other potential partners for certain additional countries."

"Sigma-Tau seeks to help improve health and quality of life for all. Our agreement to bring Zingo to European markets fits perfectly with this aim, and we are eager to make this FDA-approved product available to patients who otherwise might not have access to it for the reduction of pain associated with peripheral venous access procedures," said Ugo Di Francesco, Executive Vice President and Chief Executive Officer at Sigma-Tau.

The agreement between Anesiva and Sigma-Tau includes an upfront payment to Anesiva and transfer price, as well as milestone payments; additional terms were not disclosed.

About Zingo(TM)

Zingo(TM) is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine powder to provide topical, local analgesia to reduce the pain associated with peripheral I.V. insertions or blood draws. Zingo's rapid onset of action allows intravenous line placement or venipuncture to begin one to three minutes after administration. Zingo was approved by the U.S. Food and Drug Administration (FDA) in August 2007 to reduce the pain associated with peripheral I.V. insertions or blood draws in children three to 18 years of age. In clinical trials, the most common adverse events with Zingo were redness (erythema), red dots (petechiae) and swelling (edema).

About Sigma-Tau Group

Sigma-Tau is a leading research-based Italian pharmaceutical company with a 2007 consolidated turnover equal to approximately US$980 million, and over 2,500 employees worldwide. Therapeutic areas in which the company's research and development are focused include cardiovascular disease, metabolism, oncology, immunology, and central and nervous system disorders, with 47 projects, 30 clinical indications studied with 17 proprietary molecules, most of which are new and original. Sigma-Tau has operating subsidiaries throughout Europe and the United States and maintains a presence in all of the world's major pharmaceutical markets. For additional information about Sigma-Tau, please visit http://www.sigma-tau.it.

About Anesiva and its Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA, USA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anesiva Announces Hiring of Sales Force for FDA-Approved Product Zingo(TM)
2. Anesiva Announces Upcoming Webcasts and Conference Participation
3. Anesiva to Announce Third Quarter 2007 Financial Results and Host Webcast Conference Call on November 1, 2007
4. Anesiva to Present at BIO InvestorForum on October 11, 2007
5. Anesiva to Unveil Zingo(TM) Commercialization Plans
6. URAC Announces Four More Companies in Process to Earn New Pharmacy Quality Management Accreditations
7. MGT Capital Investments, Inc. Announces Subsidiarys Preliminary Agreement to Acquire Maydeal.com
8. Dialysis Corporation of America Announces Opening of New Dialysis Center in Ohio
9. Rural/Metro Announces Results for Fiscal 2008 Second Quarter
10. Brookdale Senior Living Announces Changes in Senior Management and Board of Directors
11. Tubbs Jones Announces Over $36 Million in Construction Projects for Cleveland VA Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
(Date:1/17/2017)... ... ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider , is proud ... Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that Mirror Mirror Beauty ... by Zeltiq, CoolSculpting is approved by the Food and Drug Administration as a safe ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health ... Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage ... is an exciting addition to our provider network, and the addition will benefit ...
(Date:1/17/2017)... , ... January 17, 2017 , ... A prescription medication ... of the fourth Cradle to Cradle Product Design Challenge , the Cradle ... a series of six circular design challenges scheduled to run through early 2018. The ...
(Date:1/17/2017)... ... 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey firm ... is launching a charity drive to raise awareness of heart disease and promote habits ... America, and is responsible for 1 in every 4 deaths at the national level ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... The report " Automated Breast Ultrasound System (ABUS) Market ... End User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional Outlook (U.S., ... , Germany , UK, France , ... , China , Japan , ... Saudi Arabia , UAE, South Africa ), ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
(Date:1/18/2017)... 2017  Astellas Pharma Inc. (President and CEO: ... its participation in Access Accelerated, a global, multi-stakeholder ... prevention, diagnostics and treatment in low-income and lower-middle ... companies and in collaboration with the World Bank ... (UICC), Astellas will work towards the United Nations ...
Breaking Medicine Technology: